Document text
Introduction to the HPV Vaccines Work Group
Oliver Brooks, MD
Chair, HPV Vaccines Work Group
Advisory Committee on Immunization Practices
October 24, 2024
National Center for Immunization & Respiratory Diseases
•HPV Vaccines Work Group re -formation announced at June 2024
ACIP meeting
•An HPV Vaccines Work Group met previously for many years, but
had been inactive since 2019
•3 meetings since July 2024Background
2
•Routine vaccination
-Age 11 or 12 years
-Can be started at age 9 years
•Catch -up vaccination
-Through age 26 years
•Shared clinical decision -making
-Age 27 –45 yearsCurrent HPV vaccination recommendations,
United States
Recommendations of the Centers for Disease Control and Prevention and the Advisory Committee on Immunization Practices
https://www.cdc.gov/vaccines/hcp/acip -recs/vacc -specific/hpv.html Number of doses
2 doses (0, 6 -12 months)
if starting series before 15th birthday
3 doses (0,1-2, 6 months)
if starting series on or after 15th birthday or if
immunocompromising condition
3
•Number of doses in the recommended HPV vaccination series
-Accumulating evidence on efficacy of HPV vaccination with fewer doses
-In 2022, the World Health Organization recommended a two -dose schedule for
persons aged 9 years or older and, a s an off -label option, a single -dose schedule
can be used for those aged 9 –20 years
-Work Group is reviewing data to inform policy for:
•two doses for persons aged 15 years and older
•one dose for persons aged 9 years and olderWork Group Terms of Reference
4
•Wording of the age for routine HPV vaccination
-Some stakeholders interested in starting vaccination at age 9 years
-Current ACIP recommendations are consistent with vaccination at age 9 years
-Work Group is considering m odification of wording to “ HPV vaccination is routinely
recommended at age 9 to 12 years” to allow more flexibility Work Group Terms of Reference
5
•Reviewed background data on the two issues being considered
•Number of doses in the recommended HPV vaccination series:
-Started GRADE process
-Planning full Evidence to Recommendations ( EtR) framework and ACIP vote at
future meeting
•Wording of the age for routine HPV vaccination:
-Reviewed related literature
-Not using GRADE
-Planning modified EtR and ACIP vote at future meetingACIP HPV Vaccines Work Group progress
6
ACIP HPV Vaccines Work Group
ACIP voting members
Oliver Brooks (chair)
Noel Brewer
Sybil Cineas
CDC Co -Leads
Carla DeSisto
Lauri MarkowitzLiaison members
Robin O'Meara (AAFP)
Angela Myers (AAP)
Linda Eckert (ACOG)
Alfonso Iorio (ACP)
Jamilia Sherls (AIM)
Sandy Fryhofer (AMA)
Sean O'Leary (IDSA)
Nicole Forbes (NACI)
Kevin Ault (NFID)
Alexandra Yonts (PIDS)
Nneka Holder (SAHM)
7Ex-Officio members
Sixun Yang (FDA)
Aimée R. Kreimer (NIH)
Eleanore Chuang (NIH)
Consultant members
Laura Makaroff (ACS)
Peter Szilagyi
Rachel Winer
Elizabeth Moore (consumer rep)
GRADE consultants
Doug Campos -Outcalt
Rebecca Morgan
Julia Gargano (DVD)
Ruth Stefanos (DVD)
Virginia Senkomago (DCPC)
Patrick Clay (DSTDP)
Harrell Chesson (DSTDP)
Shannon Stokley (ISD)
Adefemi Adeleke (ISD)
Cassandra Pingali (ISD)ACIP HPV Vaccines Work Group - CDC Staff
Elizabeth R. Unger (DHCPP)
Gitika Panicker (DHCPP)
Christine Olson (ISO)
Julianne Gee (ISO)
Hannah Rosenblum (ACIP Secretariat)
8
Today’s agenda
Introduction to policy consideration:
reduced number of dosesDr. Lauri Markowitz
CDC/NCIRD
Introduction to policy consideration:
wording of the age for routine vaccinationDr. Ruth Stefanos
CDC/NCIRD
Review of literature on HPV vaccination at
ages 9 -10 to increase coverageDr. Sarah Brewer
CDC/NCIRD
Next steps Dr. Carla DeSisto
CDC/NCIRD
9